merged_fda-journavx-suzetrigine-vertex-opioids.txt
<question_number>1</question_number>
<answer>N/A</answer>

<question_number>2</question_number>
<answer>N/A</answer>

<question_number>3</question_number>
<answer>N/A</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>0</answer>
<other>The article explicitly states the drug "cannot become addictive" because it works only on nerves outside the brain and cannot get into the brain.</other>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>N/A</answer>

<question_number>8</question_number>
<answer>N/A</answer>

<question_number>9</question_number>
<answer>N/A</answer>

<question_number>10</question_number>
<answer>N/A</answer>

<question_number>11</question_number>
<answer>lumbosacral radiculopathy</answer>
<other>The article states that suzetrigine "was no better than placebo in those with pinched nerves in the spine," which is identified as lumbosacral radiculopathy.</other>

<question_number>12</question_number>
<answer>N/A</answer>

<question_number>13</question_number>
<answer>Nav1.7 and Nav1.8</answer>

<question_number>14</question_number>
<answer>N/A</answer>

<question_number>15</question_number>
<answer>2004</answer>

<question_number>16</question_number>
<answer>N/A</answer>

<question_number>17</question_number>
<answer>N/A</answer>

<question_number>18</question_number>
<answer>0.21%</answer>
<other>Calculated from 85,000 people becoming addicted out of 40 million prescribed opioids each year (85,000/40,000,000 = 0.002125 = 0.21%)</other>

<question_number>19</question_number>
<answer>diabetic neuropathy</answer>